Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges
<p>The World Health Organization’s global health estimates in 2022 showed that primary liver cancer ranks as the sixth most common cancer globally, impacting over 866,000 patients worldwide, and is the third leading cause of cancer death globally, with a higher prevalence in Asia. Hepatocellul...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book Chapter |
| Language: | English |
| Published: |
IntechOpen
2026
|
| Subjects: | |
| Online Access: | https://www.intechopen.com/chapters/1237192 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1879164888866095104 |
|---|---|
| author | Sumou, Ingrid Karmane Peng, Xianghong |
| author_browse | Peng, Xianghong Sumou, Ingrid Karmane |
| author_facet | Sumou, Ingrid Karmane Peng, Xianghong |
| author_sort | Sumou, Ingrid Karmane |
| building | IntechOpen |
| collection | Acceso abierto |
| description | <p>The World Health Organization’s global health estimates in 2022 showed that primary liver cancer ranks as the sixth most common cancer globally, impacting over 866,000 patients worldwide, and is the third leading cause of cancer death globally, with a higher prevalence in Asia. Hepatocellular carcinoma (HCC) contributes 85–90% of primary liver cancer. Despite vaccinations and screening programs, HCC patients far too often present with advanced, unresectable disease. The underlying liver disease compromising liver function often perplexes treatment. Common etiologies include chronic viral hepatitis (types B and C), excessive alcohol consumption, and exposure to aflatoxin, with significant geographic variation. The therapeutic landscape for unresectable HCC (uHCC) is advancing with the advent of novel agents. Bona fide validation on the management of uHCC remains a challenge, especially across geographic areas. There is, at present, no consensus guideline on the optimal treatment sequence. In this chapter, we discuss the present landscape of treatment and future challenges.</p> |
| doi_str_mv | 10.5772/intechopen.1014154 |
| first_indexed | 2026-10-15T21:41:30Z |
| format | Book Chapter |
| fullrecord | <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><identifier>intech-1237192</identifier><datestamp>2026-01-26</datestamp>
<dc:title>Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges</dc:title>
<dc:creator>Ingrid Karmane Sumou</dc:creator>
<dc:creator>Xianghong Peng</dc:creator>
<dc:subject>Health Sciences</dc:subject>
<dc:description><p>The World Health Organization&rsquo;s global health estimates in 2022 showed that primary liver cancer ranks as the sixth most common cancer globally, impacting over 866,000 patients worldwide, and is the third leading cause of cancer death globally, with a higher prevalence in Asia. Hepatocellular carcinoma (HCC) contributes 85&ndash;90% of primary liver cancer. Despite vaccinations and screening programs, HCC patients far too often present with advanced, unresectable disease. The underlying liver disease compromising liver function often perplexes treatment. Common etiologies include chronic viral hepatitis (types B and C), excessive alcohol consumption, and exposure to aflatoxin, with significant geographic variation. The therapeutic landscape for unresectable HCC (uHCC) is advancing with the advent of novel agents. Bona fide validation on the management of uHCC remains a challenge, especially across geographic areas. There is, at present, no consensus guideline on the optimal treatment sequence. In this chapter, we discuss the present landscape of treatment and future challenges.</p></dc:description>
<dc:publisher>IntechOpen</dc:publisher>
<dc:date>2026-01-26</dc:date>
<dc:type>Chapter, Part Of Book</dc:type>
<dc:identifier>https://www.intechopen.com/chapters/1237192</dc:identifier>
<dc:identifier>doi:10.5772/intechopen.1014154</dc:identifier>
<dc:language>en</dc:language>
<dc:relation>ISBN:978-1-80631-118-7</dc:relation>
<dc:rights>https://creativecommons.org/licenses/by/3.0/</dc:rights>
<dc:source>https://www.intechopen.com/books/1004856 ; Liver Cancer - Recent Advances in 2026</dc:source>
</oai_dc:dc> |
| id | intech-1237192 |
| institution | IntechOpen |
| isbn | 978-1-80631-118-7 |
| language | English |
| last_indexed | 2026-10-15T21:41:30Z |
| publishDate | 2026 |
| publishDateRange | 2026 |
| publishDateSort | 2026 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | oai_dc |
| spelling | intech-12371922026-01-26 Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges Ingrid Karmane Sumou Xianghong Peng Health Sciences <p>The World Health Organization’s global health estimates in 2022 showed that primary liver cancer ranks as the sixth most common cancer globally, impacting over 866,000 patients worldwide, and is the third leading cause of cancer death globally, with a higher prevalence in Asia. Hepatocellular carcinoma (HCC) contributes 85–90% of primary liver cancer. Despite vaccinations and screening programs, HCC patients far too often present with advanced, unresectable disease. The underlying liver disease compromising liver function often perplexes treatment. Common etiologies include chronic viral hepatitis (types B and C), excessive alcohol consumption, and exposure to aflatoxin, with significant geographic variation. The therapeutic landscape for unresectable HCC (uHCC) is advancing with the advent of novel agents. Bona fide validation on the management of uHCC remains a challenge, especially across geographic areas. There is, at present, no consensus guideline on the optimal treatment sequence. In this chapter, we discuss the present landscape of treatment and future challenges.</p> IntechOpen 2026-01-26 Chapter, Part Of Book https://www.intechopen.com/chapters/1237192 doi:10.5772/intechopen.1014154 en ISBN:978-1-80631-118-7 https://creativecommons.org/licenses/by/3.0/ https://www.intechopen.com/books/1004856 ; Liver Cancer - Recent Advances in 2026 |
| spellingShingle | Health Sciences Sumou, Ingrid Karmane Peng, Xianghong Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges |
| title | Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges |
| title_full | Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges |
| title_fullStr | Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges |
| title_full_unstemmed | Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges |
| title_short | Systemic Therapy for Unresectable Hepatocellular Carcinoma: Present Landscape and Future Challenges |
| title_sort | systemic therapy for unresectable hepatocellular carcinoma present landscape and future challenges |
| topic | Health Sciences |
| url | https://www.intechopen.com/chapters/1237192 |
| work_keys_str_mv | AT sumouingridkarmane systemictherapyforunresectablehepatocellularcarcinomapresentlandscapeandfuturechallenges AT pengxianghong systemictherapyforunresectablehepatocellularcarcinomapresentlandscapeandfuturechallenges |